If you or a loved one has been diagnosed with nephrogenic systemic fibrosis as a result of exposure to gadolinium, you may be entitled to compensation.

You should act immediately to contact a lawyer experienced in matters involving dangerous pharmaceuticals.

We have represented thousands of people, including some of the largest and most important injury cases ever brought in the United States.

In the single largest damages case in the history of the world, our attorneys were selected by the Arizona Attorney General as the only Arizona law firm to represent the State against American tobacco companies. As a result, Arizona taxpayers will receive more than three billion dollars to cover the costs of treating tobacco-related illnesses, maintain educational programs to prevent young people from smoking, and fund other important State programs.

We have compiled the latest news on gadolinium-based agents. All of the news articles on this page require Adobe Acrobat to view.

If you or a loved one has been diagnosed with nephrogenic systemic fibrosis and you would like more information on your legal rights, please contact us.

The Food and Drug Administration said Wednesday it is asking manufacturers of certain contrast agents used in patients undergoing magnetic resonance imaging, or MRI scans, to place a black-box warning on the agents' packaging.

The FDA said the warning, which would apply to five gadolinium-based contrast agents, including ones made by General Electric Co.'s health-care unit and a unit of Bayer AG, would state that patients with severe kidney insufficiency are at risk for developing a debilitating, and a potentially fatal, disease known as nephrogenic systemic fibrosis, or NSF.

The FDA said the warning would also state that patients having a liver transplant or those with chronic liver disease are also at risk for developing NSF if they are experiencing kidney insufficiency of any severity.

The U.S. Food and Drug Administration (FDA) has asked manufacturers to include a new boxed warning on the product labeling of all gadolinium-based contrast agents which are used to enhance the quality of magnetic resonance imaging (MRI).

The requested warning would state that patients with severe kidney insufficiency who receive gadolinium-based agents are at risk for developing a debilitating, and a potentially fatal disease known as nephrogenic systemic fibrosis (NSF). In addition, it would state that patients just before or just after liver transplantation, or those with chronic liver disease, are also at risk for developing NSF if they are experiencing kidney insufficiency of any severity.

The FDA today ordered black-box warnings for all gadolinium-based contrast agents for magnetic resonance imaging, detailing an increased risk for nephrogenic systemic fibrosis with kidney-disease patients.

The warning alerts clinicians of possible severe kidney insufficiency in patients at risk for nephrogenic systemic fibrosis, a potentially fatal disease, who receive gadolinium-based agents. The boxed message also warns that the nephrogenic systemic fibrosis risk extends to patients with chronic liver disease including those just before or after liver transplantation.

O'Steen & Harrison, PLC presently is investigating legal claims on behalf of those harmed by gadolinium.

If you or a loved one has been diagnosed with nephrogenic systemic fibrosis, please call us toll-free at 1-800-883-8888 or submit this online contact form.